Sanders Corazon (Corsee) D. 4

What Happened Corazon D. Sanders, a director of Ultragenyx Pharmaceutical Inc. (RARE), received equity awards on 2026-05-14 totaling 21,809 shares: 7,751 restricted stock units (RSUs) and a 14,058-share derivative award. Both items were reported as acquisitions at $0.00 (these are grants, not cash purchases), and the filing was submitted on 2026-05-18.

Key Details

• Transaction date: 2026-05-14; Form 4 filed: 2026-05-18 (filed within the SEC two-business-day window).
• Grants: 7,751 RSUs (acquired at $0.00) and a 14,058-share derivative award (acquired at $0.00).
• Vesting: Footnote F1 (RSUs) and F2 (derivative/option) state each vests in full on the earlier of the company’s next Annual Meeting or May 14, 2027.
• Shares owned after the transaction: not specified in the filing.
• No sale or open-market purchase occurred — these are compensatory awards.

Context These are director compensation awards (common for boards) and do not represent an open-market purchase or sale. The derivative award is described in the filing’s footnote as an option-like award that will vest by the stated date; it does not indicate immediate exercise or sale. Such grants are routine but increase potential future dilution when/if they vest and are converted to shares.